119 related articles for article (PubMed ID: 10901449)
1. Copper bis(diphosphine) complexes: radiopharmaceuticals for the detection of multi-drug resistance in tumours by PET.
Lewis JS; Dearling JL; Sosabowski JK; Zweit J; Carnochan P; Kelland LR; Coley HM; Blower PJ
Eur J Nucl Med; 2000 Jun; 27(6):638-46. PubMed ID: 10901449
[TBL] [Abstract][Full Text] [Related]
2. In vivo and in vitro multitracer analyses of P-glycoprotein expression-related multidrug resistance.
Márián T; Szabó G; Goda K; Nagy H; Szincsák N; Juhász I; Galuska L; Balkay L; Mikecz P; Trón L; Krasznai Z
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1147-54. PubMed ID: 12830325
[TBL] [Abstract][Full Text] [Related]
3. Novel technetium (III)-Q complexes for functional imaging of multidrug resistance (MDR1) P-glycoprotein.
Crankshaw CL; Marmion M; Luker GD; Rao V; Dahlheimer J; Burleigh BD; Webb E; Deutsch KF; Piwnica-Worms D
J Nucl Med; 1998 Jan; 39(1):77-86. PubMed ID: 9443741
[TBL] [Abstract][Full Text] [Related]
4. Visualization of multidrug resistance in vivo.
Hendrikse NH; Franssen EJ; van der Graaf WT; Vaalburg W; de Vries EG
Eur J Nucl Med; 1999 Mar; 26(3):283-93. PubMed ID: 10079321
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. Design of hypoxia-targeting radiopharmaceuticals: selective uptake of copper-64 complexes in hypoxic cells in vitro.
Dearling JL; Lewis JS; Mullen GE; Rae MT; Zweit J; Blower PJ
Eur J Nucl Med; 1998 Jul; 25(7):788-92. PubMed ID: 9662602
[TBL] [Abstract][Full Text] [Related]
7. Application of SPET using technetium-99m sestamibi in brain tumours and comparison with expression of the MDR-1 gene: is it possible to predict the response to chemotherapy in patients with gliomas by means of 99mTc-sestamibi SPET?
Yokogami K; Kawano H; Moriyama T; Uehara H; Sameshima T; Oku T; Goya T; Wakisaka S; Nagamachi S; Jinnouchi S; Tamura S
Eur J Nucl Med; 1998 Apr; 25(4):401-9. PubMed ID: 9553170
[TBL] [Abstract][Full Text] [Related]
8. Novel hexakis(areneisonitrile)technetium(I) complexes as radioligands targeted to the multidrug resistance P-glycoprotein.
Herman LW; Sharma V; Kronauge JF; Barbarics E; Herman LA; Piwnica-Worms D
J Med Chem; 1995 Jul; 38(15):2955-63. PubMed ID: 7636856
[TBL] [Abstract][Full Text] [Related]
9. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex.
Piwnica-Worms D; Chiu ML; Budding M; Kronauge JF; Kramer RA; Croop JM
Cancer Res; 1993 Mar; 53(5):977-84. PubMed ID: 8094997
[TBL] [Abstract][Full Text] [Related]
10. Reversal of multidrug resistance: lessons from clinical oncology.
Bates SF; Chen C; Robey R; Kang M; Figg WD; Fojo T
Novartis Found Symp; 2002; 243():83-96; discussion 96-102, 180-5. PubMed ID: 11990784
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein versus MRP1 on transport kinetics of cationic lipophilic substrates: a comparative study using [99mTc]sestamibi and [99mTc]tetrofosmin.
Gomes CM; Abrunhosa AJ; Pauwels EK; Botelho MF
Cancer Biother Radiopharm; 2009 Apr; 24(2):215-27. PubMed ID: 19409044
[TBL] [Abstract][Full Text] [Related]
12. Involvement of glutathione in loss of technetium-99m-MIBI accumulation related to membrane MDR protein expression in tumor cells.
Moretti JL; Duran Cordobes M; Starzec A; de Beco V; Vergote J; Benazzouz F; Boissier B; Cohen H; Safi N; Piperno-Neumann S; Kouyoumdjian JC
J Nucl Med; 1998 Jul; 39(7):1214-8. PubMed ID: 9669397
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a 67Ga/68Ga radiopharmaceutical for SPECT and PET of MDR1 P-glycoprotein transport activity in vivo: validation in multidrug-resistant tumors and at the blood-brain barrier.
Sharma V; Prior JL; Belinsky MG; Kruh GD; Piwnica-Worms D
J Nucl Med; 2005 Feb; 46(2):354-64. PubMed ID: 15695797
[TBL] [Abstract][Full Text] [Related]
14. TC-99m MIBI SPECT imaging in patients with lung carcinoma: is it a functional probe of multidrug resistance genes?
Ak I; Gülbaş Z; Ocak S; Kaya E; Alataş F; Vardareli E; Metintaş M
J Comput Assist Tomogr; 2007; 31(5):795-9. PubMed ID: 17895794
[TBL] [Abstract][Full Text] [Related]
15. Imaging recognition of inhibition of multidrug resistance in human breast cancer xenografts using 99mTc-labeled sestamibi and tetrofosmin.
Liu Z; Stevenson GD; Barrett HH; Furenlid LR; Wilson DW; Kastis GA; Bettan M; Woolfenden JM
Nucl Med Biol; 2005 Aug; 32(6):573-83. PubMed ID: 16026704
[TBL] [Abstract][Full Text] [Related]
16. Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands.
Sun X; Wuest M; Weisman GR; Wong EH; Reed DP; Boswell CA; Motekaitis R; Martell AE; Welch MJ; Anderson CJ
J Med Chem; 2002 Jan; 45(2):469-77. PubMed ID: 11784151
[TBL] [Abstract][Full Text] [Related]
17. 99mTc-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer.
Mubashar M; Harrington KJ; Chaudhary KS; Lalani el-N; Stamp GW; Sinnett D; Glass DM; Peters AM
J Nucl Med; 2002 Apr; 43(4):519-25. PubMed ID: 11937596
[TBL] [Abstract][Full Text] [Related]
18. Clinical imaging of multidrug resistance in cancer.
Del Vecchio S; Ciarmiello A; Salvatore M
Q J Nucl Med; 1999 Jun; 43(2):125-31. PubMed ID: 10429507
[TBL] [Abstract][Full Text] [Related]
19. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression.
Cordobes MD; Starzec A; Delmon-Moingeon L; Blanchot C; Kouyoumdjian JC; Prévost G; Caglar M; Moretti JL
J Nucl Med; 1996 Feb; 37(2):286-9. PubMed ID: 8667063
[TBL] [Abstract][Full Text] [Related]
20. Radiopharmaceuticals for assessment of multidrug resistance P-glycoprotein-mediated drug transport activity.
Sharma V
Bioconjug Chem; 2004; 15(6):1464-74. PubMed ID: 15546216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
